Contents

Reviews

Current Status of Biological Therapies for the Treatment of Metastatic Melanoma. T. TANG, R. ELDABAJE, L. YANG (San Francisco, CA, USA) ........................................................................................................................... 3229

The Use of Complementary and Alternative Medicine in Scandinavia. J. NILSSON, M. KÄLLMAN, U. ÖSTLUND, G. HOLGERSSON, M. BERGQVIST, S. BERGSTRÖM (Gavle; Umea, Sweden) .................................................. 3243

Non-routine Tracers for PET Imaging of High-grade Glioma. G. FROSINA (Genoa, Italy) ......................... 3253

Experimental Studies

Premalignant Oral Lesion Cells Elicit Increased Cytokine Production and Activation of T-cells. S.D. JOHNSON, C. LEVINGTON, M.R.I. YOUNG (Charleston, SC, USA) .................................................................................................................... 3261

Delivery of siRNA Using Cationic Liposomes Incorporating Stearic Acid-modified Octa-Arginine. D. YANG, Y. LI, Y. QI, Y. CHEN, X. YANG, Y. LI, S. LIU, R.J. LEE (Changchun, Jilin; Zhuhai, Guangdong, PR China; Columbus, OH, USA) ........................................................................................................................................ 3271

Profiling of Vascular Endothelial Growth Factor Receptor Heterogeneity Identifies Protein Expression-defined Subclasses of Human Non-small Cell Lung Carcinoma. T.R. HOLZER, A.D. FULFORD, L. O’NEILL REISING, D.M. NEDDERMAN, X. ZHANG, L.E. BENJAMIN, A.E. SCHADE, A. NASIR (Indianapolis, IN, USA) ................................................................................................................................................... 3277

Histone Methylation by Temozolomide; A Classic DNA Methylating Anticancer Drug. T. WANG, A.J. PICKARD, J.M. GALLO (Carson, CA; New York, NY, USA) ........................................................................................................ 3289

Contents continued on the back cover
Announcement - Call for Papers

Special Issue of ANTICANCER RESEARCH 2016 on NEW ANTICANCER AGENTS

TOPICS:

A. Experimental Studies on “New Anticancer Agents”
   1. Synthesis and evaluation in vitro and in vivo
   2. Mechanism of action
   3. Reversal of resistance to anticancer agents

B. Clinical Studies on “New Anticancer Agents”
   1. Pharmacology
   2. Phase I and II Studies
   3. Combination chemotherapy
   4. Immunotherapeutic agents
   5. New methodologies in drug delivery and therapy

Deadline for submission of articles: August 22, 2016
Publication date: November 2016

Information:
Dr. George J. Delinasios, e-mail: journals@iiar-anticancer.org
General Policy. CANCER GENOMICS & PROTEOMICS (CGP) welcomes submissions of original high quality articles and reviews on all aspects of the application of genomic and proteomic technologies to experimental and clinical cancer research. The journal’s scientific spectrum includes: (a) molecular causes of carcinogenesis, cancer progression and metastasis; (b) structural and functional aspects of genes in the cancer cell; (c) advances in genomic and proteomic technologies applicable to cancer research; (d) anticancer drug design and drug development.

A main aim of CGP is to ensure the prompt and confidential review, and rapid publication of original works and reviews, generally within 1-3 months from submission or 1-2 months from acceptance.

CGP is published bimonthly by the International Institute of Anticancer Research (IIAR) and is available online with Stanford University HighWire Press. The IIAR is a member of UICC. For more information please visit our website www.cgp.iiarjournals.org.

Editorial Office: International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., P.O. Box 22, Kapandriti, Attiki 19014, Greece. Tel: +30 22950 52945, Fax: +30 22950 53389.

U.S. Branch: Anticancer Research Inc., USA, 111 Bay Avenue, Highlands, NJ, USA.

E-mail: journals@iiar-anticancer.org; IIAR websites: www.iiar-anticancer.org and www.iiarjournals.org

A Selection of Recent Articles

Identification of Novel Biomarker and Therapeutic Target Candidates for Diagnosis and Treatment of Follicular Adenoma. X. LAI, S. CHEN (Indianapolis, IN, USA)

A Low-density Antigen Array for Detection of Disease-associated Autoantibodies in Human Plasma. R.I. SOMIARI, R. SUTPHEN, K. RENGANATHAN, S. RUSSELL, S.A. SOMIARI (Johnstown; Windber, PA; Tampa, FL, USA)

WNT/β-catenin Signaling Pathway and Downstream Modulators in Low- and High-grade Glioma. T. DENYSENKO, L. ANNOVAZZI, P. CASSONI, A. MELCARNE, M. MELLAI, D. SCHIFFER (Vercelli; Turin, Italy)

Identification of Endogenous Controls for Use in miRNA Quantification in Human Cancer Cell Lines. M.K. DAS, R. ANDREASSEN, T.B. HAUGEN, K. FURU (Oslo, Norway)


Doxorubicin Affects Expression of Proteins of Neuronal Pathways in MCF-7 Breast Cancer Cells. M. PETROVIC, C. SIMILLION, P. KRUZLIAK, J. SABO, M. HELLER (Kosice, Slovak Republic; Bern, Switzerland; Brno, Czech Republic)

Molecular Mechanisms of Bone Metastasis. U.H. WEIDLE, F. BIRZELE, G. KOLLMORGHEN, R. RUGER (Penzberg, Germany)

Identification of Prognostically Relevant Chromosomal Abnormalities in Routine Diagnostics of Multiple Myeloma Using Genomic Profiling. E. KJELDSEN (Aarhus, Denmark)

MTA1 Is Up-regulated in Colorectal Cancer and Is Inversely Correlated with Lymphatic Metastasis. J. LI, L. YE, P.-H. SUN, L. SATHERLEY, R. HARGEST, Z. ZHANG, W.G. JIANG (Cardiff, UK; Beijing, PR China)


Significant Association of Caveolin-1 and Caveolin-2 with Prostate Cancer Progression. S. SUGIE, S. MUKAI, K. YAMASAKI, T. KAMIBEPPU, H. TSUKINO, T. KAMOTO (Miyazaki, Japan)

Delayed 5-Fluorouracil Toxicity with Uridine Triacetate in Patients with Dihydropyrimidine Dehydrogenase Deficiency. M.W. SAIF, R.B. DIASIO (Boston, MA; Rochester, MN, USA)
Reviews